Content Related to Ketamine

Video: Update on Clinical Utilization of Ketamine in Suicide Prevention, Including Psychedelics

Alan F. Schatzberg, MD, Stanford University School of Medicine, presents as part of the 2023 Suicide-Focused Assessment and Treatment: An Update for Professionals course.

Video: Lecture – Pediatric Depression: Evidence-Based and Emerging Treatments, Including Ketamine

Presented by Michael Bloch, MD, MS, Child Study Center – Nancy Black Simches Visiting Scholar Series lecture

In the Media: Is Ketamine Therapy the Future of Mental Health Treatment?

Watch Dr. Robert C. Meisner discuss what is known about ketamine and how it is used to treat mental illness.

Neurotherapeutics Clinic Opens at McLean SouthEast in Middleborough

In an effort to deliver cutting-edge therapies to patients with major depression with convenient access to their local communities, McLean Hospital is expanding its treatment services with the opening of a neurotherapeutics clinic at the McLean SouthEast campus at 52 Oak Street in Middleborough...

In the Media: Ketamine and Esketamine for Depression – Lessons Learned in Clinical Practice

Paula Bolton, MS, CNP, ANP-BC, and Courtney Miller, RN, ADN, BA, discuss the lessons they have learned in using ketamine and esketamine with patients with treatment-resistant depression and suicidal thoughts.

In the Media: Ketamine for Depression – What It Feels Like and Who It Can Help

Dr. Robert C. Meisner gives insight into the lack of requirements for ketamine treatment.

In the Media: IV Ketamine Has Gone Mainstream as a Depression Treatment – But Is It Right for You?

Dr. Robert C. Meisner outlines McLean’s data-driven, evidence-based ketamine treatment program.

In the Media: The Art of Turning Ketamine Therapy Into TikTok Content

Dr. Robert C. Meisner suggests adding other evidence-based treatments in collaboration with ketamine therapy.

In the Media: Ketamine Therapy Helped My Depression. I Wish It Were More Accessible.

Dr. Robert C. Meisner suggests realistic goals when starting ketamine treatment for depression.

Video: Clinical Use of Ketamine in Suicide Prevention

Presented by Alan F. Schatzberg, MD, Stanford School of Medicine Since acute prevention of suicide in people with mood disorders remains a major unsolved issue, ketamine, and more recently esketamine, has received much attention as an antidepressant treatment. In this talk, Schatzberg reviews the...

In the Media: Ketamine for Depression Could Help Relieve Some of the Mental Health Burden Caused by Pandemic, Experts Say

Dr. Robert C. Meisner on how mental health issues caused by the pandemic have led to an increased interest in ketamine treatment.

In the Media: Esketamine Effective and Costly Treating Treatment-Resistant Depression

Dr. Eric L. Ross and collaborators examine the cost-effectiveness of esketamine, a novel intranasally dosed antidepressant for patients with treatment-resistant depression.

In the Media: Ketamine for Depression Still Too Expensive for Widespread Use

Research by Dr. Eric L. Ross finds that esketamine, a nasal spray to treat severe depression, is currently too expensive for widespread use.

In the Media: Ketamine – The Good, The Bad, The Future of Treating Depression?

Listen to Dr. Robert C. Meisner on the use of ketamine to treat depression.

Study Examines the Cost-Effectiveness of Esketamine

A paper authored by researchers from McLean Hospital examines the feasibility of esketamine, a nasal spray to treat severe depression. Titled “Cost-Effectiveness of Esketamine Nasal Spray for Patients With Treatment-Resistant Depression in the United States,” the paper was published on July 7 in...

In the Media: San Diego VA Moves Suicidal Veterans Off ‘Life-Saving Treatment,’ Against Doctor’s Pleas

Robert C. Meisner, MD, from McLean’s Ketamine Service, discusses ketamine response rates and the need for more options for treating depression.

Increased Volume and New Services Spur Change in McLean’s Psychiatric Neurotherapeutics Program

On any given day at McLean’s Psychiatric Neurotherapeutics Program, some 50 patients come through the door for ECT (electroconvulsive therapy), 20 or more for TMS (transcranial magnetic stimulation), and about four for the program’s new ketamine infusion service . “That’s a lot of people,” said...

Staff Profile: Brian W. Boyle, MD

Brian W. Boyle, MD, is a staff psychiatrist at McLean Hospital’s Psychiatric Neurotherapeutics Program, where he cares for patients with treatment-resistant depression using ketamine and electroconvulsive therapy (ECT). He is interested in the treatment of patients who struggle with both mood and...

Staff Profile: Hayley Parét, MSN, PMHNP-BC

Hayley Parét, MSN, PMHNP-BC, is a board-certified psychiatric mental health nurse practitioner. Breaking the barriers of traditional nursing practice, Ms. Parét is one of the first nurse practitioners to become both an ECT and ketamine provider at McLean’s Psychiatric Neurotherapeutics Program. Ms...

Staff Profile: Violeta Valdivia, MD

Violeta Valdivia, MD, is a staff psychiatrist at McLean’s Electroconvulsive Therapy (ECT) Service. She completed one year of post-residency training at Massachusetts General Hospital for electroconvulsive therapy and transcranial magnetic stimulation therapy. Dr, Valdivia also evaluates patients for...

Ketamine Related Content

Type of Content